Valproic acid-carbapenem interaction: Report of six cases and a review of the literature

Drug Metabolism and Drug Interactions

Volumn 24, Issue 2-4, 2009, Pages 153-182

  Tobin, Jennifer K ^a   Golightly, Larry K ^a,b   Kick, Steven D ^a,c   Jones, Michael A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenem; Ertapenem; Imipenem; Interaction; Meropenem; Seizure; Valproic acid

Indexed keywords

ERTAPENEM; IMIPENEM; MEROPENEM; VALPROIC ACID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; EPILEPSY; FEMALE; GRAND MAL SEIZURE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MALE; MENINGITIS; OBSERVATIONAL STUDY; PNEUMONIA; RETROSPECTIVE STUDY; SEIZURE; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 77950613313     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2009.24.2-4.153     Document Type: Article

References (105)

1. Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy: a review. Epilepsia 1975; 16: 549-573.
2. Pinder RM, Brogden RN, Speight TM, Avery GS. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 1977; 13: 81-123.
3. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120. (Pubitemid 44086745)
4. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblended randomised controlled trial. Lancet 2007; 369: 1016-1027.
5. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006; 13: 445-450. (Pubitemid 43823356)
6. Bowden CL, Perlis RH, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159 (Suppl): 1-50. (Pubitemid 34274969)
7. Snow V, Weiss K, Wall EM, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137: 840-849. (Pubitemid 35334454)
8. Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006; 13: 560-572. (Pubitemid 43873628)
9. Bradley JS, Garau J, Lode H, Rolston KVI, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11: 93-100. (Pubitemid 29114967)
10. th Ed. New Rochelle, NY: The Medical Letter, 2008; 37-85.
11. Calandra GB, Wang C, Aziz M, et al. The safety profile of imipenem/ cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986; 18 (Suppl E): 193-202.
12. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (Suppl A): 207-223.
13. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53 (Suppl 2): 75-81.
14. Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron [Letter]. J Antimicrob Chemother 1997; 39: 295-296. (Pubitemid 27116436)
15. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit 1998; 20: 396-400. (Pubitemid 28359989)
16. De Turck BJG, Diltoer MW, Cornelis PJWW, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin [Letter]. J Antimicrob Chemother 1998; 42: 563-564.
17. Llinares Tello F, Bosacoma Ros N, Hernández Prats C, Climent Grana E, Selva Otaolaurruchi J, Ordovás Baines JP. Interacción farmacocinética entre ácido valproico y antibióticos carbapenémicos: descripción de tres casos. Farm Hosp 2003; 27: 258-263.
18. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol 2004; 31: 232-234. (Pubitemid 39221255)
19. Pérez Plasencia A, Soy D, Nicolas JM. Interación farmacocinética entre el ácido valproico y el meropenem [Letter]. Med Clin (Barc) 2004; 123: 38-39.
20. Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol 2005; 20: 456-457. (Pubitemid 40873057)
21. Clause D, Decleire P-Y, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic interaction between valproic acid and meropenem [Letter]. Intensive Care Med 2005; 31: 1293.
22. Coves-Orts FJ, Borrás-Blasco J, Navarro-Ruiz A, Murcia-López A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother 2005; 39: 533-537. (Pubitemid 40270921)
23. Lam YWF. Drug-drug interactions: valproic acid taken with meropenem may result in seizures. Brown University Psychopharmacology Update 2005; 16 (6): 2-3.
24. Sala Piñol F, Padullés Zamora N, Hidalgo Albert E, et al. Interacción farmacocinética entre ácido valproico y meropenem. An Pediatr (Barc) 2006; 64: 93-95. (Pubitemid 43302201)
25. Perea Falomir M, Roura Poch P, Higueruelo Demasón S, Garcia Gil VJ. Descripción de un caso de interacción farmacocinética entre ácido valproico y imipenem [Letter]. Farm Hosp 2006; 30: 316-317.
26. Cabanes Mariscal MA, Sánchez López P, Alvarez Herranz P, Chamorro Merino G. Pharmacokinetic interaction between valproic acid and ertapenem [Letter]. Farm Hosp 2006; 30: 313-315. (Pubitemid 46102056)
27. Fudio S, Carcas A, Piñana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther 2006; 31: 393-396. (Pubitemid 44060205)
28. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007; 27: 1202-1205.
29. Spriet I, Meersseman W, De Troy E, Wilmer A, Casteels M, Willems L. Meropenem-valproic acid interaction in patients with cefepime-associated status epilepticus. Am J Health Syst Pharm 2007; 64: 54-58. (Pubitemid 46395708)
30. Lee S-G, Kim J-H, Joo JY, Kwon OH. Seven cases of decreased serum valproic acid concentration during concomitant use of carbapenem antibiotics. Korean J Lab Med 2007; 27: 338-343.
31. Spriet I, Gowens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother 2007; 41: 1130-1136. (Pubitemid 47122549)
32. Eimil-Ortiz M, Aguirre-Mollehuanca D, Sierra-Limpo A, Fontán-Torado C, Villar-Villar ME. Meropenem y ácido valproico: una asociación peligrosa [Letter]. Rev Neurol 2008; 46: 124-125.
33. Baraboutis IG, Marangos MN, Skoutelis A, Bassaris H. Meropenem-aggravated seizure activity in progressive myoclonus epilepsy [Letter]. Int J Antimicrob Agents 2008; 31: 177-179.
34. th Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 8-29.
35. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 1983; 14: 38-42.
36. Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985; 10: 155-163.
37. Horn JR, Hansten PJ, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-680.
38. Mori H, Takashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007; 39: 647-657. (Pubitemid 350208726)
39. Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. J Pharm Pharmacol 2001; 53: 823-829. (Pubitemid 32529725)
40. Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Int J Pharm 2002; 233: 253-256. (Pubitemid 34230437)
41. Kojima S, Nadai M, Kitaichi K, Wang L, Nabeshima T, Hasegawa T. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother 1998; 42: 3136-3140. (Pubitemid 28553731)
42. Shirkey RJ, Jellett LB, Kappatos DC, Maling TJB, Macdonald A. Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease. Eur J Clin Pharmacol 1985; 28: 447-452.
43. Highley MS, De Bruijn EA. Erythrocytes and the transport of drugs and endogenous compounds. Pharm Res 1996; 13: 186-195. (Pubitemid 126423735)
44. Omoda K, Murakami T, Yumoto R, et al. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. J Pharm Sci 2005; 94: 1685-1693. (Pubitemid 41360863)
45. Ogawa K, Yumoto R, Hamada N, Nagai J, Takano M. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Epilepsy Res 2006; 71: 76-87. (Pubitemid 44233201)
46. Dutta S, Faught E, Limdi N. Valproate protein binding following rapid intravenous administration of high dose of valproic acid in patients with epilepsy. J Clin Pharm Ther 2007; 32: 365-371. (Pubitemid 47063160)
47. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982; 31: 642-649.
48. Fischer W, Praetor K, Metzner L, Neubert RHH, Brandsch M. Transport of Valproate at intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells: mechanism and substrate specificity. Eur J Pharm Biopharm 2008; 70: 486-492.
49. Golden PL, Brouwer KR, Pollack GM. Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis. Pharm Res 1993; 10: 1765-1771.
50. Naora K, Ichikawa N, Nishimura N, Hirano H, Shen DD, Iwamoto K. Saturable transport of valproic acid in rat choroid plexus in vitro. J Pharm Sci 1996; 85: 423-426. (Pubitemid 26105711)
51. 2- valproic acid in rabbits. Drug Metab Dispos 1997; 25: 1337-1346.
52. Adkison KDK, Artru AA, Powers KM, Shen DD. Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J Pharmacol Exp Ther 1994; 268: 797-805.
53. Ho RH, Kim RB. Perspectives in clinical pharmacology. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-277.
54. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007; 320: 331-343. (Pubitemid 46025748)
55. Nies AT, Jedlitschky G, König J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129: 349-360.
56. Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-π in human glioma. J Neuro-Oncol 2005; 74: 113-121. (Pubitemid 41478906)
57. Jedlitschky G, Burchel B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
58. Wijnholds J, Mol CAAM, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97: 7476-7481. (Pubitemid 30431488)
59. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005; 4: 855-863. (Pubitemid 40767130)
60. Wielinga P, Hooijberg JH, Gunnarsdottir S, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005; 65: 4425-4430. (Pubitemid 40775682)
61. Dallas S, Schlichter L, Bendayan R. Multidrug resistance protein (MRP) 4-and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia J Pharmacol Exp Ther 2004; 309: 1221-1229. (Pubitemid 38669713)
62. Schrenck D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann H-M. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 2001; 120: 51-57. (Pubitemid 32375070)
63. Maher JM, Cherrington NJ, Slitt AL, Klaasen CD. Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci 2006; 78: 2219-2225.
64. Suzuki T, Sasaki H, Kuh H-J, et al. Detailed structural analyses on both human MRP5 and mouse mrp5 transcripts. Gene 2000; 242: 167-173. (Pubitemid 30064502)
65. Ravna AW, Sylte I, Sager G. Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor Biol Med Model 2007; 4: 33. http://www.tbiomed.com/content/4/1/ 33.
66. Hammes GG. Unifying concept for the coupling between ion pumping and ATP hydrolysis or synthesis. Proc Natl Acad Sci USA 1982; 79: 6881-6884.
67. Igarashi Y, Aoki KF, Mamitsuka H, Kuma K, Kanehisa M. The evolutionary repertoires of the eukaryotic-type ABC transporters in terms of the phytogeny of ATP-binding in eukaryotes and prokaryotes. Mol Biol Evol 2004; 21: 2149-2160. (Pubitemid 39391992)
68. P1b integron overexpresses two efflux pumps and lacks OprD. J Antimicrob Chemother 2007; 60: 132-135. (Pubitemid 47073286)
69. Giske CG, Buarø L, Sundsfjord A, Wretlind B. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microb Drug Resist 2008; 14: 23-30.
70. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid-1988. Clin Pharmacokinet 1988; 15: 367-389.
71. Granneman GR, Wang SI, Machinist JM, Kesterson JW. Aspects of the metabolism of valproic acid. Xenobiotica 1984; 14: 375-387.
72. Pollack GM, McHugh WB, Gengo FM, Ermer JC, Shen DD. Accumulation and washout kinetics of valproic acid and its active metabolites. J Clin Pharmacol 1986; 26: 668-676.
73. Yamamura N, Imura K, Naganuma H, Nishimura K. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos 1999; 27: 724-730. (Pubitemid 29252448)
74. Yamamura N, Imura-Miyoshi K, Naganuma H. Panipenem, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos 2000; 28: 1484-1486.
75. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004; 32: 1383-1391. (Pubitemid 39564558)
76. Yokogawa K, Iwashita S, Kubota A, et al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. Pharm Res 2001; 18: 1320-1326. (Pubitemid 32846327)
77. Dupuis A, Pariat C, Courtois P, Couet W, Bouquet S. Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations. Fundam Clin Pharmacol 2000; 14: 163-165. (Pubitemid 30204978)
78. Patel JB, Giles RE. Meropenem: evidence of a lack of preconvulsive tendency in mice. J Antimicrob Chemother 1989; 24 (Suppl A): 307-309.
79. Zhanel GC, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-1052.
80. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-694. (Pubitemid 35176853)
81. Morag M, Myslobodsky M. Benzodiazepine antagonists abolish electrophysiological effects of sodium valproate in the rat. Life Sci 1982; 30: 1671-1677.
82. Shephard RA, Stevenson D, Jenkinson S. Effects of valproate on hyponeophagia in rats: competitive antagonism with Picrotoxin and non-competitive antagonism with RO 15-1788. Psychopharmacology 1985; 86: 313-317.
83. Shephard RA, Hamilton MS. Chlordiazepoxide and valproate enhancement of saline drinking by nondeprived rats: effects of bicuculline, picrotoxin, and RO 15-788. Pharmacol Biochem Behav 1989; 33: 285-290.
84. A receptor antagonists. J Med Chem 1992; 35; 1969-1977.
85. A response inhibition by β-lactam antibiotics in the pyramidal neurons of the rat cerebral cortex. Br J Pharmacol 1995; 116: 3014-3020.
86. Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of the C-2 side chain. J Antibiot (Tokyo) 1995; 48: 408-416.
87. Shimada J, Hori S, Kanemitsu K, Shoji Y, Nakashio S, Yanagawa A. A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res 1992; 18: 377-381. (Pubitemid 23089091)
88. de Sarro A, Imperatore C, Mastroeni P, de Sarro G. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice. J Pharm Pharmacol 1995; 47: 292-296.
89. Williams PD, Bennett DB, Comereski CR. Animal model for evaluating the convulsive liability of β-lactam antibiotics. Antimicrob Agents Chemother 1988; 32: 758-760.
90. de Sarro G, Ammendola D, Nava F, de Sarro A. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res 1995; 671: 131-140.
91. A, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993; 37: 199-202.
92. Day IP, Goudie J, Nishiki K, Williams. PD. Correlation between in vitro and in vivo models of preconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995; 76: 239-243.
93. Jin C, Jung I, Ku H-J, et al. Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared to existing congeners. Toxicology 1999; 138: 59-67. (Pubitemid 29484459)
94. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability or doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006; 222: 114-124. (Pubitemid 44275125)
95. 3H]dihydropicrotoxin binding sites at the benzodiazepine-GABA receptor-ionophore complex. Brain Res 1981; 223: 218-222.
96. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007; 51: 333-355.
97. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 1998; 54: 721-741. (Pubitemid 28137704)
98. Petroff OAC, Rothman DL, Behar KL, Hyder F, Mattson RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 1999; 8: 120-127. (Pubitemid 29176760)
99. Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 2000; 133: 334-339. (Pubitemid 30459540)
100. Hassel B, Iversen EG, Gjerstad L, Taubøll E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001; 77: 1285-1292. (Pubitemid 32523681)
101. Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand Suppl 2003; 180: 16-22. (Pubitemid 37352605)
102. Hirata-Koizumi M, Saito M, Miyake S, Hasegawa R. Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid, and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. Int J Clin Pharm Ther 2007; 32: 177-185. (Pubitemid 46449709)
103. MEDWATCH: The FDA Safety Information and Adverse Event Reporting Program. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)-March 2008. http://www.fda.gov/med watch/SAFETY/2008/mar08.htm.
104. Ohnhaus EE, Breckinridge AM, Park BK. Urinary excretion of 6β-hydroxycortisol and the time course of measurement of enzyme induction in man. Eur J Clin Pharmacol 1989; 36: 39-46.
105. Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006; 6: 575-589.